108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
电针预防经期相关偏头痛的疗效和安全性：一项初步随机对照试验的研究方案
Authors Liu X, Jiao R, Zheng Y, Liu Y , Yu G, Shi J, Wang W , Wang W
Received 18 June 2025
Accepted for publication 29 September 2025
Published 8 October 2025 Volume 2025:17 Pages 3541—3555
DOI https://doi.org/10.2147/IJWH.S548053
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Matteo Frigerio
Xinkun Liu,1,* Ruimin Jiao,2,* Yaqing Zheng,1,* Yan Liu,3 Guangxian Yu,1 Jiaxiang Shi,1 Wei Wang,1 Weiming Wang1
1Department of Acupuncture and Moxibustion, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People’s Republic of China; 2Department of Traditional Chinese Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of China; 3Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weiming Wang, Department of Acupuncture and Moxibustion, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange St., Xicheng District, Beijing, People’s Republic of China, Email wangweiming1a1@163.com
Background: Acupuncture, a well-established non-pharmacological intervention, has displayed promise in migraine management, but high-quality evidence for its effectiveness in menstrually related migraine (MRM) prophylaxis remains scarce. This pilot randomized controlled trial will evaluate the feasibility, efficacy, and safety of electroacupuncture (EA) for MRM prevention and provide evidence-based support for future large-scale trials.
Methods/Design: This single-center, participant- and assessor-blinded, sham-controlled pilot trial will assign 40 eligible patients with MRM in a 1:1 ratio to the EA or sham EA (SEA) group via block randomization. Participants will begin treatment on day − 3 of each menstrual cycle (estimated according to the previous cycle), receiving 1– 2 sessions during the first week (from day − 3 to +4 of menstruation) and 2– 3 sessions per week for the following 3 weeks. The intervention period will last 12 weeks and total 30 sessions, followed by 12 weeks of follow-up. The primary outcome is the change from baseline in standardized monthly headache days (SMHDs) at week 12. Secondary outcomes include the MRM cure rate, responder rate for MRM (≥ 50% reduction in SMHDs), changes in headache severity and medication use, quality of life (Migraine-Specific Quality of Life Questionnaire v2.1), psychological status (Hospital Anxiety and Depression Scale), headache-related disability (Headache Impact Test-6), global impression of change (Patient’s Global Impression of Change), and feasibility measures. All analyses will follow the intention-to-treat principle with two-sided P < 0.05 considered significant.
Discussion: As the first sham-controlled RCT specifically targeting MRM, this study will apply a menstrual cycle-tailored EA protocol and use uniformly assessed SMHDs as the primary outcome to enhance methodological rigor and novelty. The findings are expected to provide preliminary evidence and inform the design of future large-scale trials.
Trial Registration: The trial protocol has been registered at ClinicalTrials.gov (NCT07023926).
Keywords: menstrually related migraine, electroacupuncture, clinical trial protocol
1Department of Acupuncture and Moxibustion, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People’s Republic of China; 2Department of Traditional Chinese Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of China; 3Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weiming Wang, Department of Acupuncture and Moxibustion, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange St., Xicheng District, Beijing, People’s Republic of China, Email wangweiming1a1@163.com
Background: Acupuncture, a well-established non-pharmacological intervention, has displayed promise in migraine management, but high-quality evidence for its effectiveness in menstrually related migraine (MRM) prophylaxis remains scarce. This pilot randomized controlled trial will evaluate the feasibility, efficacy, and safety of electroacupuncture (EA) for MRM prevention and provide evidence-based support for future large-scale trials.
Methods/Design: This single-center, participant- and assessor-blinded, sham-controlled pilot trial will assign 40 eligible patients with MRM in a 1:1 ratio to the EA or sham EA (SEA) group via block randomization. Participants will begin treatment on day − 3 of each menstrual cycle (estimated according to the previous cycle), receiving 1– 2 sessions during the first week (from day − 3 to +4 of menstruation) and 2– 3 sessions per week for the following 3 weeks. The intervention period will last 12 weeks and total 30 sessions, followed by 12 weeks of follow-up. The primary outcome is the change from baseline in standardized monthly headache days (SMHDs) at week 12. Secondary outcomes include the MRM cure rate, responder rate for MRM (≥ 50% reduction in SMHDs), changes in headache severity and medication use, quality of life (Migraine-Specific Quality of Life Questionnaire v2.1), psychological status (Hospital Anxiety and Depression Scale), headache-related disability (Headache Impact Test-6), global impression of change (Patient’s Global Impression of Change), and feasibility measures. All analyses will follow the intention-to-treat principle with two-sided P < 0.05 considered significant.
Discussion: As the first sham-controlled RCT specifically targeting MRM, this study will apply a menstrual cycle-tailored EA protocol and use uniformly assessed SMHDs as the primary outcome to enhance methodological rigor and novelty. The findings are expected to provide preliminary evidence and inform the design of future large-scale trials.
Trial Registration: The trial protocol has been registered at ClinicalTrials.gov (NCT07023926).
Keywords: menstrually related migraine, electroacupuncture, clinical trial protocol